AOD-9604 Dosage Calculator
Calculate AOD-9604 injection volumes. Pre-filled for a 5mg vial with 2ml BAC water (2,500 mcg/ml). Typical 300mcg dose = 12 units.
AOD-9604 is a synthetic fragment of human growth hormone (amino acids 177–191 plus a terminal tyrosine). In preclinical models it was reported to stimulate lipolysis and inhibit lipogenesis without the growth-promoting effects of full hGH. Its phase 2/3 human obesity trials failed to show significant weight loss versus placebo, development was discontinued, and it is not FDA-approved.
For a 5mg AOD-9604 vial: add 2ml of bacteriostatic water → concentration is exactly 2500 mcg/ml. For the standard 300mcg daily dose, inject 0.12ml (12 units) on a 100-unit syringe.
Dose Reference Table
Pre-calculated for a 5mg vial + 2ml BAC water = 2,500 mcg/ml concentration. Using a 100-unit (1ml) insulin syringe.
| Dose | Inject Volume (ml) | Syringe Units |
|---|---|---|
| 200mcg | 0.080 ml | 8 units |
| 250mcg | 0.100 ml | 10 units |
| 300mcg | 0.120 ml | 12 units |
| 500mcg | 0.200 ml | 20 units |
| 1000mcg | 0.400 ml | 40 units |
About AOD-9604
AOD-9604 (Advanced Obesity Drug) is a modified fragment of human growth hormone (hGH), specifically the C-terminal fragment corresponding to amino acids 177–191 of the hGH molecule. It was originally developed by Monash University as a potential anti-obesity treatment because preclinical studies showed it retained hGH's fat-metabolizing properties without the growth-promoting or insulin-desensitizing effects of full hGH.
AOD-9604 is thought to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat accumulation) by interacting with beta-3 adrenergic receptors, similar to the mechanism of hGH on adipose tissue. This makes it an interesting compound for body composition research. Human trials did not confirm the preclinical promise: the phase 2b obesity program failed to show statistically significant weight loss versus placebo, clinical development was discontinued in 2007, and AOD-9604 is not FDA-approved — no proven weight-loss efficacy exists in humans. Source: Mendias & Awan, Sports Medicine 2026 (regulatory status of unapproved peptides, incl. AOD-9604).
AOD-9604 is typically supplied in 5mg vials. Using 2ml of bacteriostatic water yields a concentration of 2,500 mcg/ml. Community protocols commonly reference 250–500mcg per day by subcutaneous injection, sometimes in the morning or before exercise; no clinical evidence supports these doses or timing strategies, since the human trials were discontinued before dosing was established.
How this calculator works
Every result comes from the same three formulas used for any lyophilized peptide: concentration (mcg/ml) = vial mg × 1,000 ÷ BAC water ml; injection volume (ml) = desired dose mcg ÷ concentration; syringe units = injection volume ml × 100 on a U-100 syringe.
For the preset AOD-9604 setup on this page: a 5mg vial mixed with 2ml of bacteriostatic water gives a concentration of 2,500 mcg/ml. A 300mcg dose then needs 0.12ml, which is 12 units on a 100-unit insulin syringe.
The full methodology, with worked examples and the assumptions behind each formula, is on the methodology page.
Accuracy & limitations
The arithmetic itself is exact — the same inputs always produce the same output. Real-world accuracy depends on things outside the calculator: actual vial contents can vary slightly from the labeled amount within manufacturing tolerance, the BAC water volume should be measured carefully, and syringe readings are taken at the bottom edge of the plunger. Reconstituted peptides also degrade over time (the common guidance is to use within about 28 days refrigerated), which the math does not model. This tool does arithmetic only — it does not recommend doses, and it is not medical advice.
Last reviewed: September 2026 · Content, formulas and sources checked by Kanika